ABL Bio Inc (298380)
KOSDAQ · Korea · prices in KRW · close of 27 Oct 2026
Key indicators
| Last close | KRW 40,850.00 |
|---|---|
| 52-week range | 39,700.00 – 257,500.00 |
| Return, 1 month / 3 months | −19.6% / −43.7% |
| Return, 1 year / 3 years | −56.7% / +152.9% |
| Trend | Below its 200-day average |
| RSI (14) | 32 |
| Volatility (1 year) | 91.7% |
| Worst drawdown (1 year) | -83.5% |
| Average daily value traded | 21,128.56M KRW |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
ABL Bio Inc is a biotechnology company based in South Korea that researches and develops antibody-based medicines. Its work centres on bispecific antibodies, which are engineered to bind two targets at once, and it has programmes in immuno-oncology and neuroscience. The company advances its drug candidates through preclinical and clinical testing, and it works with pharmaceutical partners on research collaborations and licensing arrangements. Its customers and collaborators are mainly drug developers and research organisations rather than patients directly.
ABL Bio Inc trades under the code 298380 on the KOSDAQ in Korea, with its price quoted in South Korean won (KRW). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
ABL Bio Inc (298380) trades on the KOSDAQ in Korea. It last closed at KRW 40,850.00 on 27 October 2026.
Its price-based Market X-Ray is 22 out of 100 (a weak price profile), ranking 1,696 of 1,833 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 56.7% and over the last three months it fell 43.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on KOSDAQ
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 2 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -66.7% | ||
| From 52-week high | -83.4% | ||
| Momentum | 7 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -43.7% | ||
| 6-month return | -76.3% | ||
| 12-month return, skipping the last month | -46.2% | ||
| Stability (higher is calmer) | 13 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 91.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -83.5% | ||
| Liquidity | 96 · Strong | Trades actively. | |
| Average daily value traded | 21,128.56M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −8.6% |
|---|---|
| 1 month | −19.6% |
| 3 months | −43.7% |
| 6 months | −76.3% |
| 1 year | −56.7% |
| 3 years | +152.9% |
| 5 years | +77.2% |
Signals
| 50-day / 200-day average | 60,564.00 / 122,823.50 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 3,372.64 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on KOSDAQ; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.